Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

2024/06/03 by Changsong Qi, Chang Liu, Jifang Gong +22 · 1 voice · 2 citations
Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses

paper · doi:10.1038/s41591-024-03037-z

crossref issued 2024/06/03 · crossref published 2024/06/03 · crossref published-online 2024/06/03 · openalex publication_date 2024/06/03 · crossref created 2024/06/03 · crossref published-print 2024/08/01 · crossref deposited 2025/01/24 · openalex created_date 2025/10/10 · crossref indexed 2026/07/29 · openalex updated_date 2026/07/30

Citations

• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
• Cancer statistics, 2024
• Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials

Cited by

• Turning “trashed” genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy

Discussions

• 22/31 #TumorBoardTuesday 🏫Mini Tutorial 19🏫 ORR 38.8%, DCR 91.8%, mDOR 6.4 mos Among 10 pts with PDAC: 2 PR, 7 SD, 1 PD doi.org/10.1038/s41591-024-03037-z [bsky, 4 points, 2 comments]